Sugi Predict

Sugi Predict / Compounds / SCHEMBL4370508

SCHEMBL4370508

SCHEMBL4370508

Cn1cc[n+](CCCS(=O)(=O)[O-])c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PABPC1 P11940 1/20 0.43
▸ EIF4H Q15056 1/20 0.43
▸ CTDSP1 Q9GZU7 1/20 0.43
▸ ALDH1A1 P00352 6/20 0.36
▸ KDM4E B2RXH2 4/20 0.36
▸ RXFP1 Q9HBX9 1/20 0.36
▸ HTT P42858 1/20 0.35
▸ HPGD P15428 2/20 0.34
▸ GAA P10253 1/20 0.34
▸ BBOX1 O75936 2/20 0.33
▸ MAPT P10636 3/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ THRB P10828 1/20 0.32
▸ RECQL P46063 1/20 0.32
▸ GMNN O75496 1/20 0.31
▸ LMNA P02545 1/20 0.31
▸ TP53 P04637 1/20 0.31
▸ TSHR P16473 1/20 0.31
▸ MAPK1 P28482 1/20 0.31
▸ THPO P40225 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4363080 0.95 PABPC1 (0.39) PABPC1EIF4HCTDSP1ALDH1A1KDM4E
SCHEMBL4023086 0.88 MEN1 (0.36) SMN1; SMN2
SCHEMBL28143118 0.88 MEN1 (0.36) SMN1; SMN2
SCHEMBL4266264 0.88 — —
SCHEMBL7742084 0.87 KDM4E (0.37) PABPC1EIF4HCTDSP1ALDH1A1KDM4E
Sulfuric Acid SCHEMBL18260144 0.85 PABPC1 (0.31) PABPC1EIF4HCTDSP1
Sulfuric Acid SCHEMBL18260145 0.85 PABPC1 (0.31) PABPC1EIF4HCTDSP1
SCHEMBL28652452 0.85 KDM4E (0.37) PABPC1ALDH1A1KDM4ERXFP1HTT
SCHEMBL1111608 0.84 HTT (0.34) PABPC1EIF4HCTDSP1ALDH1A1KDM4E
SCHEMBL1992347 0.84 PABPC1 (0.33) PABPC1EIF4HCTDSP1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023021885-A1 ELECTROLYTIC SOLUTION FOR CAPACITOR AND CAPACITOR カーリットホールディングス株式会社 2023-02-23 — — WO claimed
WO-2023013368-A1 METHOD FOR PRODUCING SOLID ELECTROLYTIC CAPACITOR カーリットホールディングス株式会社 2023-02-09 — — WO claimed
US-20090118558-A1 Dehydration Process BP P.L.C. (GB) 2009-05-07 — — US claimed
US-20250174409-A1 SOLID ELECTROLYTE CAPACITOR AND METHOD FOR MANUFACTURING SAME CARLIT CO., LTD. (JP) 2025-05-29 — — US disclosed
US-20240285766-A1 Liquid Protein Formulations Containing Ionic Liquids EAGLE BIOLOGICS, INC. 2024-08-29 — — US disclosed
US-11986526-B2 Liquid protein formulations containing 4-ethyl-4-methylmorpholinium methylcarbonate (EMMC) EAGLE BIOLOGICS, INC. (US) 2024-05-21 — — US disclosed
CN-117700381-A Method for preparing bis- (5-formylfurfuryl) ether by catalyzing 5-hydroxymethylfurfural with ionic liquid catalyst 中国科学院大连化学物理研究所 2024-03-15 — — CN disclosed
WO-2023171344-A1 SOLID ELECTROLYTE CAPACITOR AND METHOD FOR MANUFACTURING SAME カーリットホールディングス株式会社 2023-09-14 — — WO disclosed
WO-2023021885-A1 ELECTROLYTIC SOLUTION FOR CAPACITOR AND CAPACITOR カーリットホールディングス株式会社 2023-02-23 — — WO disclosed
WO-2023013368-A1 METHOD FOR PRODUCING SOLID ELECTROLYTIC CAPACITOR カーリットホールディングス株式会社 2023-02-09 — — WO disclosed
US-11471479-B2 Polysaccharide and nucleic acid formulations containing viscosity-lowering agents EAGLE BIOLOGICS, INC. (US) 2022-10-18 — — US disclosed
US-20180047889-A1 ELECTROACTIVE ACTUATOR, MECHANICAL DEVICE INCLUDING THE SAME, AND POLYMER ELECTROLYTE POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) 2018-02-15 — — US disclosed
US-9833513-B2 Liquid protein formulations for injection comprising 1-butyl-3-methylimidazolium methanesulfonate and uses thereof EAGLE BIOLOGICS, INC. (US) 2017-12-05 — — US disclosed
EP-3200804-A1 POLYSACCHARIDE AND NUCLEIC ACID FORMULATIONS CONTAINING VISCOSITY-LOWERING AGENTS Eagle Biologics, Inc. (US) 2017-08-09 — — EP disclosed
US-20170108752-A1 ELECTROCHROMIC-THERMOCHROMIC DEVICES AND METHODS OF MAKING AND USE THEREOF UNITED STATES DEPARTMENT OF ENERGY 2017-04-20 — — US disclosed
EP-3043774-A2 LIQUID PROTEIN FORMULATIONS CONTAINING IONIC LIQUIDS Arsia Therapeutics, Inc. (US) 2016-07-20 — — EP disclosed
WO-2016054259-A1 POLYSACCHARIDE AND NUCLEIC ACID FORMULATIONS CONTAINING VISCOSITY-LOWERING AGENTS Arsia Therapeutics, Inc. (US) 2016-04-07 — — WO disclosed
WO-2015038811-A2 LIQUID PROTEIN FORMULATIONS CONTAINING IONIC LIQUIDS Arsia Therapeutics, Inc. (US) 2015-03-19 — — WO disclosed
US-20150071922-A1 LIQUID PROTEIN FORMULATIONS CONTAINING IONIC LIQUIDS EAGLE BIOLOGICS, INC. 2015-03-12 — — US disclosed
US-20090118558-A1 Dehydration Process BP P.L.C. (GB) 2009-05-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11471479-B2 Polysaccharide and nucleic acid formulations containing viscosity-lowering agents RNGTT, SNRPA, SNRNP200 PABPC1 46/4885EIF4H 2112/4885CTDSP1 123/4885
US-20240285766-A1 Liquid Protein Formulations Containing Ionic Liquids IGFBP5, IGFBP1, IGF2BP1 PABPC1 909/4885EIF4H 444/4885CTDSP1 1905/4885
US-20150071922-A1 LIQUID PROTEIN FORMULATIONS CONTAINING IONIC LIQUIDS IGFBP5, IGFBP1, IGF2BP1 PABPC1 909/4885EIF4H 444/4885CTDSP1 1905/4885
US-11986526-B2 Liquid protein formulations containing 4-ethyl-4-methylmorpholinium methylcarbonate (EMMC) MLEC, DMPK, CD14 PABPC1 800/4885EIF4H 100/4885CTDSP1 2788/4885
US-20090118558-A1 Dehydration Process ADH1A, ADH1C, ADH5 PABPC1 4579/4885EIF4H 1539/4885CTDSP1 1227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.